

Paper No. _____
Filed: November 23, 2015

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,
INNOPHARMA INC., INNOPHARMA LLC,
MYLAN PHARMACEUTICALS INC., and MYLAN INC.,
Petitioners

v.

SENJU PHARMACEUTICAL CO., LTD.,
Patent Owner

Case IPR2016-00090
U.S. Patent 8,871,813

PATENT OWNER'S MANDATORY NOTICES
PURSUANT TO 37 C.F.R. § 42.8

Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner Senju Pharmaceutical Co., Ltd. (“Senju”) hereby submits the following mandatory notices in connection with this proceeding.

I. SENJU’S POWER OF ATTORNEY

A Power of Attorney appointing lead and back-up counsel is being filed concurrently with these Notices.

II. SENJU’S MANDATORY NOTICES

(a) 37 C.F.R. § 42.8(b)(1): Real Party-in-Interest

The real party-in-interest for the Patent Owner is Senju Pharmaceutical Co., Ltd. Other real parties-in-interest include Bausch & Lomb Inc., and Bausch & Lomb Pharma Holdings Corp.

(b) Related Matters

1. Judicial

The patent challenged here, U.S. Patent 8,871,813 (“the ’813 patent”), has been asserted in the following litigations:

Case Caption	Case Number	Court	Filing Date
<i>Senju Pharm. Co., Ltd., Bausch & Lomb, Inc. and Bausch & Lomb Pharma Holdings Corp. v. Innopharma Licensing, Inc., Innopharma Licensing, LLC, Innopharma, Inc., and Innopharma LLC</i>	1:14-cv-06893	D.N.J.	Nov. 3, 2014
<i>Senju Pharm. Co., Ltd., Bausch & Lomb Inc. and Bausch & Lomb Pharma Holdings Corp. v. Lupin, Ltd. and Lupin Pharms., Inc.</i>	1:15-cv-00335	D.N.J.	Jan. 16, 2015

<i>Senju Pharm. Co. Ltd., Bausch & Lomb Inc. and Bausch & Lomb Pharma Holdings Corp. v. Apotex Inc. and Apotex Corp.</i>	1:15-cv-00336	D.N.J.	Jan. 16, 2015
<i>Senju Pharm. Co. Ltd., Bausch & Lomb Inc. and Bausch & Lomb Pharma Holdings Corp. v. Paddock Labs., LLC, L. Perrigo Co., and Perrigo Co.</i>	1:15-cv-00337	D.N.J.	Jan. 16, 2015
<i>Senju Pharm. Co. Ltd., Bausch & Lomb Inc. and Bausch & Lomb Pharma Holdings Corp. v. Paddock Labs., LLC, L. Perrigo Co., and Perrigo Co.</i>	1:15-cv-00087	D.Del.	Jan. 26, 2015
<i>Senju Pharm. Co. Ltd., Bausch & Lomb Inc. and Bausch & Lomb Pharma Holdings Corp. v. InnoPharma Licensing, Inc., Innopharma Licensing, LLC, Innopharma, Inc., Innopharma, LLC, Mylan Pharms., Inc., and Mylan Inc.</i>	1:15-cv-03240	D.N.J.	May 8, 2015
<i>Senju Pharm. Co. Ltd., Bausch & Lomb Inc. and Bausch & Lomb Pharma Holdings Corp. v. Watson Labs., Inc., Actavis, Inc. and Actavis Pharma, Inc.</i>	1:15-cv-05591	D.N.J.	Jul. 16, 2015

There are four other related patents currently involved in parallel district court proceedings, U.S. Patents Nos. 8,129,431 (“the ’431 patent”) 8,669,290 (“the ’290 patent”), 8,754,131 (“the ’131 patent”), and 8,927,606 (“the ’606 patent”). As the Patent Owner reads 37 C.F.R. § 42.8, Patent Owner is not required to individually identify these proceedings, but if the Board prefers them identified, Patent Owner will do so.

2. Administrative

Petitioner filed concurrently with this petition two other petitions for *inter partes* review: (1) IPR2016-00089 of the ’131 patent, and (2) IPR2016-00091 of the ’606 patent. Patent Owner identifies additional administrative matters related to this patent family:

Case Caption	IPR No.	Patent	Filed
<i>Metrics, Inc. v. Mayne Pharma, and Johnson Matthey, Inc. v. Senju Pharm. Co., Ltd, Bausch & Lomb, Inc., and Bausch & Lomb Pharma Holdings Corp.</i>	IPR2014-01041	8,129,431	June 26, 2014
<i>Metrics, Inc. v. Mayne Pharma, and Johnson Matthey, Inc. v. Senju Pharm. Co., Ltd, Bausch & Lomb, Inc., and Bausch & Lomb Pharma Holdings Corp.</i>	IPR2014-01043	8,669,290	June 26, 2014
<i>Innopharma Licensing, Inc., Innopharma Licensing, LLC, Innopharma, Inc., Innopharma LLC, Mylan Pharm. Inc., and Mylan Inc. v. Senju Pharm. Co., Ltd, Bausch & Lomb, Inc., and Bausch & Lomb Pharma Holdings Corp.</i>	IPR2015-00903	8,129,431	Mar. 19, 2015
<i>Innopharma Licensing, Inc., Innopharma Licensing, LLC, Innopharma, Inc., Innopharma LLC, Mylan Pharm. Inc., and Mylan Inc. v. Senju Pharm. Co., Ltd, Bausch & Lomb, Inc., and Bausch & Lomb Pharma Holdings Corp.</i>	IPR2015-00902	8,669,290	Mar. 19, 2015
<i>Lupin Ltd. and Lupin Pharm. Inc. v. Senju Pharm. Co., Ltd,</i>	IPR2015-01099	8,669,290	April 23, 2015
<i>Lupin Ltd. and Lupin Pharm. Inc. v. Senju Pharm. Co., Ltd,</i>	IPR2015-01097	8,754,131	April 23, 2015
<i>Lupin Ltd. and Lupin Pharm. Inc. v. Senju Pharm. Co., Ltd,</i>	IPR2015-01105	8,871,813	April 23, 2015
<i>Lupin Ltd. and Lupin Pharm. Inc. v. Senju Pharm. Co., Ltd,</i>	IPR2015-01100	8,927,606	April 23, 2015
<i>Lupin Ltd. and Lupin Pharm. Inc. v. Senju Pharm. Co., Ltd, Bausch & Lomb, Inc., and Bausch & Lomb Pharma Holdings Corp.</i>	IPR2015-01871	8,129,431	Sept. 9, 2015

(b) 37 C.F.R. § 42.8(b)(3) and (4): Lead and Back-Up Counsel, and Service Information

Senju designates the following counsel to transact all business in the United States Patent & Trademark Office associated with the above-captioned proceeding.

Lead Counsel	Back-Up Counsel
Bryan C. Diner (Reg. No. 32,409) Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Avenue, NW Washington, DC 20001-4413 Phone: (202) 408-4116 Fax: (202) 408-4400 Email: Bryan.Diner@finnegan.com	Justin J. Hasford (Reg. No. 62,180) Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Avenue, NW Washington, DC 20001-4413 Phone: (202) 408-4175 Fax: (202) 408-4400 Email: Justin.Hasford@finnegan.com Joshua L. Goldberg (Reg. No. 59,369) Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Avenue, NW Washington, DC 20001-4413 Phone: (202) 408-6092 Fax: (202) 408-4400 Email: Joshua.Goldberg@finnegan.com

Please address all correspondence regarding this proceeding to lead and back-up counsel. Senju also consents to electronic service by email.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.